No Data
No Data
Zhejiang Zhenyuan Share (000705.SZ): The Shangyu Bio-Synthesis project is progressing smoothly and is expected to begin trial production by the end of this year.
Zhejiang Zhenyuan Share (000705.SZ) stated on the investor interaction platform on July 19 that the Shangyu Biological Synthesis Project of the company is progressing smoothly and is expected to commence trial production by the end of this year.
Zhejiang Zhenyuan Share (000705.SZ) plans to acquire 10.89% equity from minority shareholders of Zhenyuan Chain.
Zhejiang Zhenyuan Share (000705.SZ) announced that the company plans to acquire... at a purchase price of 35.8172 million yuan...
Zhejiang Zhenyuan (000705.SZ) plans to pay 0.6 yuan for every 10 shares in 2023, excluding interest on June 7
Zhejiang Zhenyuan (000705.SZ) issued an announcement. The company's 2023 equity distribution plan is: to all shares...
Zhejiang Zhenyuan (000705.SZ): Zhenyuan Pharmaceutical plans to acquire 100% of the shares of two wholly-owned subsidiaries of Zhenyuan Chemical and Zhenyuan Supply Chain
Gelonghui, May 20 | Zhejiang Zhenyuan (000705.SZ) announced that the second interim meeting of the 11th board of directors of the company in 2024 reviewed and passed the “Proposal on the Wholly-owned Subsidiary Zhenyuan Pharmaceutical to Acquire 100% Shaoxing Zhenyuan Pharmaceutical Management Co., Ltd. (hereinafter referred to as “Zhenyuan Pharmaceutical”) and Zhejiang Zhenyuan Pharmaceutical Supply Chain, a wholly-owned subsidiary, agreed to acquire Shaoxing Zhenyuan Medical Device Chemical Reagent Co., Ltd. (hereinafter referred to as “Zhenyuan Pharmaceutical”) and Zhejiang Zhenyuan Pharmaceutical Supply Chain Chain Management Co., Ltd. (below
Zhejiang Zhenyuan (000705.SZ): The subsidiary Zhenyuan Biotech is building a production line for histidine and other products, which is expected to be tested by the end of this year
Gelonghui, May 7 | Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the company's subsidiary Zhenyuan Biotech is building production lines for histidine, levodopa, tyrosine and other products, which are expected to be put into trial production by the end of this year and officially put into production in 2025.
Zhejiang Zhenyuan (000705.SZ): Net profit of 19.245.99 million yuan in the first quarter increased 3.67% year-on-year
Gelonghui, April 29丨Zhejiang Zhenyuan (000705.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 1,045 billion yuan, down 4.87% year on year; net profit attributable to shareholders of listed companies was 19.245.99 million yuan, up 3.67% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 18.5337 million yuan, up 2.16% year on year; basic earnings per share were 0.0576 yuan
No Data